Topic: Current issues in HPV testing: Implications for the elimination target (webinar in French)
Webinar date: 27 August 2021
Moderator: Marc Steben MD, DESS, CCFP, FCFP
Speaker: Mario Poljak MD, PhD
Panelists: Namory Keita & Marc Arbyn PhD, MSc, MD
In this webinar, the presentation of Prof Mario Poljak was used with French subtitles and the panelists commented on the findings and responded to questions from the audience in French. While considering the cervical cancer elimination target from WHO before the COVID-19 pandemic, we had the following objectives regarding HPV testing for our webinar in French:
- Discuss the need to use HPV testing to reach WHO objectives
- Review the quality and availability of HPV tests
- Address the challenges in the distribution chain of HPV tests due to COVID-19
- Discuss new opportunities for more effective cervical cancer prevention as a result of COVID-19 pandemic
Topic: Your patient is HPV+: What is next?
Webinar date: 13 July 2021
Moderator: Karen Canfell
Speaker: Marc Arbyn, PhD, MSc, MD
Panelist: Mark Schiffman, MD, MPH
Given the strong evidence that HPV-based screening is more effective than cytology or naked visual inspection after application of acetic acid, more and more countries have switched or are in the phase of switching towards screening using validated HPV assays. However, no consensus exists on how to triage HPV+ women. A comprehensive review of the literature on this topic provides clues to answer this question.
This webinar covered the following learning objectives and questions:
• When do we need a triage strategy after an HPV test?
• What are the best parameters for a triage strategy?
• Are the strategies for LMIC different from those of HIC?
Topic: Elimination of cervical cancer for 2030: Lessons from implementation of new screening paradigms (webinar in Spanish)
Webinar date: 16 June 2021
Webinar lead: Mauricio Maza, MD MPH
Moderator: Silvana Luciani
Speakers: Silvina Arrossi, Socióloga, MSc, PhD and Karla Alfaro, MD MPH
The International Papillomavirus Society organised its first regional webinar in Spanish.
The experts spoke about the challenges of WHO Goals for screening and treatment. The two speakers presented their local perspectives with the audience – from research on HPV self-sampling in Argentina and from the screen and treat strategy of El Salvador.
Topic: Cervical cancer vaccination and screening in the Asia Pacific during the pandemic: Where do we go from here?
Webinar date: 15 May 2021
Speakers: Dr. Suresh Kumarasamy, Prof. Suzanne Garland, Prof. Yin Ling Woo, Prof. Fiona Russell, Dr. Tsetsegsaikhan Batmunkh
Moderator: Dr. Ida Ismail Pratt and Dr. Ginni Mansberg
The International Papillomavirus Society and the APAC HPV Coalition organised a joint webinar on “Cervical cancer vaccination and screening in the Asia pacific during the pandemic: Where do we go from here?”. The aim of this webinar was to contribute to the goal put forward by the WHO for the elimination of cervical cancer global strategy. During this very interactive webinar, the panel of speakers identified main challenges in the Asia Pacific in cervical cancer screening and prevention in the COVID era to focus on towards achieving the goal. Recommendations for the Asia Pacific in terms of short-term and long-term actions were also made.
Topic: The Future of HPV Research – Capitalizing on Current Opportunities
Webinar date: 22 April 2021
Speakers: Prof. Mario Poljak & Dr. Anja Sterbenc, Prof. Gina Ogilvie & Dr. Robine Donken
Moderator: Dr Elisabeth McClymont
The goal of this young investigators’ webinar was to inspire early career HPV professionals with useful ideas for future research. The mentee/mentor pairs presented their ideas on promising topics for laboratory and public health research. The focus of research over the next 10 years was discussed and knowledge gaps were identified.
The webinar ended with a live Q&A session.
Topic: HPV: A Virus we ALL can Beat: Accelerating progress against HPV-related cancer in the era of COVID-19
Webinar date: 4 March 2021
Dr. Joel Palefsky (host) M.D. Infectious Disease Specialist, Professor of Medicine and Laboratory Medicine UCSF
Dr Princess Nothemba Simelela, Assistant Director-General for Family, Women, Children and Adolescents at WHO
Prof. Margaret Stanley, President IPVS, Emeritus Professor of Epithelial Biology in the Department of Pathology, University of Cambridge
Mr. Peter Baker, Director of Global Action on Men’s Health and HPV Vaccination Advocate
Dr. Satish Gopal, Director, Center for Global Health National Cancer Institute
Ms. Patti Murillo Casa, Cervical Cancer Survivor, Advocate, Founder of anewcamino.com
Moderator: Mr. Rageh Omaar, ITV News International Affairs Editor, presenter of current affairs
The International Papillomavirus Society (IPVS) hosted a high level panel discussion on International HPV Awareness Day March 4th, 2021. Leading experts examined the challenges and opportunities that the COVID pandemic has created in the battle to beat HPV and eliminate HPV-related cancer. Moderated by ITV International Affairs editor Rageh Omaar and hosted by Infectious Disease Specialist Dr. Joel Palefsky, this discussion targets health care professionals, public policy makers and HPV specialists.
Topic: HPV Latency: Is it real and does it matter?
Webinar date: 17 February 2021
Speakers: Prof. John Doorbar & Prof. Anna Barbara Moscicki
Moderator: Prof. Margaret Stanley
Epidemiology studies have shown intermittent detection of the same HPV type occurs in some women. In addition, women that report celibacy have been shown to have incident infections. These observations have brought into question the role of latency vs new cervical infections from either a partner or autoinoculation. Data will be presented that show the strong association with sexual behavior and repeat detection. Clinical data shows that a positive HPV cervical cancer screening test preceded by a negative test is associated with very little risk of CIN 3+ suggesting these are new infections. However, this also suggests that if this is a latent infection, clinically it may not be relevant as well. Data will be shown that intermittent positive tests over prolonged periods, however, do represent risk of CIN 3+ in the rare case.